Ex-Theseus execs extend GIST mission by taking helm of IDRx
Concentra Biosciences’ spread-betting on biotech acquisitions has finally reeled in another win in 2023, with Theseus Pharmaceuticals taking up the offer of the buyout.
CAMBRIDGE, Mass., Nov. 27, 2023 /PRNewswire/ -- On November 22, 2023, the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an unsolicited joint letter from funds and persons affiliated with Foresite Capital, LLC (collectively, Foresite) and funds and persons affiliated with OrbiMed Advisors LLC (collectively, OrbiMed), in which Foresite and OrbiMed indicated their intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock of the Company not already owned by Foresite or OrbiMed in a going-private transaction.
Four months after a safety signal blew Theseus Pharmaceuticals’ quest to develop a gastrointestinal stromal tumor (GIST) treatment off course, the biotech is shrinking its head count by almost three-quarters.
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference
CAMBRIDGE, Mass., July 13, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that it is discontinuing enrollment in the ongoing phase 1/2 study and terminating development of THE-630 in patients with gastrointestinal stromal tumors (GIST).
CAMBRIDGE, Mass., May 25, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced initial dose escalation data from the ongoing phase 1/2 trial of THE-630 in patients with advanced gastrointestinal stromal tumors (GIST).
CAMBRIDGE, Mass., May 11, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced business highlights and reported financial results for the first quarter ended March 31, 2023.